Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    GA01 - IASLC General Assembly

    • 15:00 - 16:00
    • 9/12/2021
    • Location: Program Auditorium
    • Type: Highlights
    • Track: N.A.
    • +

      GA01.01 - Welcome

      15:00 - 15:00  |  Presenter: Tetsuya Mitsudomi

      • Abstract

      No abstract available for this presentation

    • +

      GA01.02 - Recognition of Outgoing & Incoming IASLC Board of Directors

      15:00 - 15:00  |  Presenter: Tetsuya Mitsudomi, Heather Wakelee

      • Abstract

      No abstract available for this presentation

    • +

      GA01.03 - Scientific Activities Report

      15:00 - 15:00  |  Presenter: Giorgio Vittorio Scagliotti

      • Abstract

      No abstract available for this presentation

    • +

      GA01.04 - Financial Report

      15:00 - 15:00  |  Presenter: John Skadow

      • Abstract

      No abstract available for this presentation

    • +

      GA01.05 - IASLC State of the State

      15:00 - 15:00  |  Presenter: Kristin Richeimer (IASLC Interim CEO)

      • Abstract

      No abstract available for this presentation

    • +

      GA01.06 - IASLC President Parting Comments

      15:00 - 15:00  |  Presenter: Tetsuya Mitsudomi

      • Abstract

      No abstract available for this presentation

    • +

      GA01.07 - Wrap Up & Adjourn

      15:00 - 15:00  |  Presenter: Heather Wakelee

      • Abstract

      No abstract available for this presentation

  • +

    MTE05 - Meet the Expert - Pharmaceutical/Biotech Industry

    • 15:00 - 16:00
    • 9/12/2021
    • Location: IASLC Booth via Industry Hub and Exhibit Hall
    • Not for CME Credit
    • Type: Meet the Expert Sessions
    • Track: N.A.
    • +

      MTE05.01 - Pharmaceutical/Biotech Industry

      15:00 - 16:00  |  Presenter: Bob Marchesani

      • Abstract

      No abstract available for this presentation

  • +

    MTE06 - Meet the Expert - Academic and Community Crossover - Increasing Interdisciplinary Collaboration

    • 15:00 - 16:00
    • 9/12/2021
    • Location: IASLC Booth via Industry Hub and Exhibit Hall
    • Not for CME Credit
    • Type: Meet the Expert Sessions
    • Track: N.A.
    • +

      MTE06.01 - Academic and Community Crossover - Increasing Interdisciplinary Collaboration

      15:00 - 16:00  |  Presenter: Sarah B Goldberg

      • Abstract

      No abstract available for this presentation

  • +

    PL03 - Plenary 3: Screening: The Global Landscape, Progress, and Future Directions (Japanese, Mandarin, Spanish Translation Available)

    • 16:15 - 17:15
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL03.01 - Lung Cancer Screening in Europe: Current Status

      16:15 - 16:27  |  Presenter: Ugo Pastorino

      • Abstract

      No abstract available for this presentation

    • +

      PL03.02 - Lung Cancer Screening in Latin America: Current Status and Challenges

      16:27 - 16:39  |  Presenter: Ricardo Santos

      • Abstract

      Loading...

    • +

      PL03.03 - Lung Cancer Screening in Asia

      16:39 - 16:51  |  Presenter: Li FAN

      • Abstract

      No abstract available for this presentation

    • +

      PL03.04 - Radiomics in Lung Cancer Radiation Treatment Assessment: Recent Progress and Future Directions

      16:51 - 17:03  |  Presenter: Fang-Fang Yin

      • Abstract

      No abstract available for this presentation

    • +

      PL03.05 - Live Discussion with Speakers

      17:03 - 17:15

      • Abstract

      No abstract available for this presentation

  • +

    MA09 - Predictive Markers for Immunotherapy

    • 17:30 - 18:30
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      MA09.01 - LCMC3: Immune Cell Subtypes Predict Nodal Status and Pathologic Response After Neoadjuvant Atezolizumab in Resectable NSCLC

      17:30 - 17:35  |  Presenter: Filiz Oezkan

      • Abstract

      Loading...

    • +

      MA09.02 - SAKK 16/14 - T-Cell Receptor Repertoire Metrics Predict Response to Neoadjuvant Durvalumab in Patients With Stage IIIA(N2) NSCLC 

      17:35 - 17:40  |  Presenter: Sacha I Rothschild

      • Abstract

      Loading...

    • +

      MA09.03 - Peripheral CD8+ T Cells Predicts Immune-Related Adverse Events and Survival in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy

      17:40 - 17:45  |  Presenter: Kan Wu

      • Abstract

      Loading...

    • +

      MA09.04 - Discussant

      17:45 - 18:00  |  Presenter: Benjamin Levy

      • Abstract

      No abstract available for this presentation

    • +

      MA09.05 - PD1-Positive Tertiary Lymphoid Structure as a Predictive Factor of Durable Clinical Effect in Immunotherapy for NSCLC

      18:00 - 18:05  |  Presenter: Yuki Matsumura

      • Abstract

      Loading...

    • +

      MA09.06 - Mature Tertiary Lymphoid Structures in Lung Adenocarcinoma Are Associated With Better Progression Free Survival

      18:05 - 18:10  |  Presenter: Rebecca C Obeng

      • Abstract

      Loading...

    • +

      MA09.07 - Genomic Landscape and Clinical Outcomes With Immune Checkpoint Inhibitors in NF1-Mutant NSCLC

      18:10 - 18:15  |  Presenter: Marcelo Vailati Negrao

      • Abstract

      Loading...

    • +

      MA09.08 - Discussant

      18:15 - 18:30  |  Presenter: Sabina Berezowska

      • Abstract

      No abstract available for this presentation

  • +

    MA10 - Screening and Early Detection: An Overview

    • 17:30 - 18:30
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Screening and Early Detection
    • +

      MA10.01 - Prospective Evaluation of the International Lung Screening Trial (ILST) Protocol for Management of First Screening LDCT 

      17:30 - 17:35  |  Presenter: Renelle Myers

      • Abstract

      Loading...

    • +

      MA10.02 - Lung Cancer Detected By Screening, Incidental Lung Nodule Program and Neither: A Prospective Observational Study

      17:35 - 17:40  |  Presenter: Raymond Uyiosa Osarogiagbon

      • Abstract

      Loading...

    • +

      MA10.03 - Balance Between Decreased False Positives and Delayed Diagnosis in Lung Cancer Screening

      17:40 - 17:45  |  Presenter: Rowena Yip

      • Abstract

      Loading...

    • +

      MA10.04 - Discussant

      17:45 - 18:00  |  Presenter: Mary Pasquinelli

      • Abstract

      No abstract available for this presentation

    • +

      MA10.05 - Potential of CT and PET-Based Radiomics for the Diagnosis of Lung Adenocarcinomas Indicated for Limited Resection

      18:00 - 18:05  |  Presenter: Nobuyuki Yoshiyasu

      • Abstract

      Loading...

    • +

      MA10.06 - Factors Associated with Lung Cancer Screening Adherence Among Patients with Negative Baseline Nodule Finding

      18:05 - 18:10  |  Presenter: Mehrad Bastani

      • Abstract

      Loading...

    • +

      MA10.08 - Discussant

      18:15 - 18:30  |  Presenter: Nir Peled

      • Abstract

      No abstract available for this presentation

  • +

    OA13 - Topics of Pleural Mesothelioma

    • 17:30 - 18:30
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
    • +

      OA13.01 - S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma

      17:30 - 17:40  |  Presenter: Anne Tsao

      • Abstract

      Loading...

    • +

      OA13.02 - Socioeconomic Disparities in Access to Treatment and Survival in Operable Malignant Pleural Mesothelioma in the United States

      17:40 - 17:50  |  Presenter: Estelamari Rodriguez

      • Abstract

      Loading...

    • +

      OA13.03 - Type M1 and Type M2 Macrophages Are Associated With Patient Survival in Malignant Pleural Mesothelioma

      17:50 - 18:00  |  Presenter: Hely Tytti Ollila

      • Abstract

      Loading...

    • +

      OA13.04 - Chromosomal Rearrangements and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors

      18:00 - 18:10  |  Presenter: Farhad Kosari

      • Abstract

      Loading...

    • +

      OA13.05 - Discussant

      18:10 - 18:20  |  Presenter: Harvey Pass

      • Abstract

      No abstract available for this presentation

    • +

      OA13.06 - Live Discussion with Speakers

      18:20 - 18:30

      • Abstract

      No abstract available for this presentation

  • +

    MA11 - New Biological Insights for Targeted Therapies

    • 18:45 - 19:45
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Tumor Biology and Systems Biology: Basic and Translational Science
    • +

      MA11.01 - Development of Novel EGFR Mutant NSCLC Mouse Models and Murine Cell Lines: New Tools for NSCLC Research

      18:45 - 18:50  |  Presenter: Emily K Kleczko

      • Abstract

      Loading...

    • +

      MA11.02 - Targeting HER2 Exon 20–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib

      18:50 - 18:55  |  Presenter: Han Han

      • Abstract

      Loading...

    • +

      MA11.03 - Phase Separation Orchestrates EML4-ALK Signaling and Promotes Tumorigenesis

      18:55 - 19:00  |  Presenter: Zhen Qin

      • Abstract

      Loading...

    • +

      MA11.04 - Discussant

      19:00 - 19:15  |  Presenter: Katerina Politi

      • Abstract

      No abstract available for this presentation

    • +

      MA11.05 - Lysyl Oxidase Inhibition Triggers Phenotypic Transition

      19:15 - 19:20  |  Presenter: YUEQING CHEN

      • Abstract

      Loading...

    • +

      MA11.06 - Multi-Omic Characterization of Lung Tumors Implicates AKT and MYC Signaling in Adenocarcinoma to Squamous Cell Transdifferentiation

      19:20 - 19:25  |  Presenter: Alvaro Quintanal-Villalonga

      • Abstract

      Loading...

    • +

      MA11.07 - Lung Squamous Cell Carcinoma Prognosis Based on Ferroptosis DNA Methylation Status

      19:25 - 19:30  |  Presenter: Xuequan Wang

      • Abstract

      Loading...

    • +

      MA11.08 - Discussant

      19:30 - 19:45  |  Presenter: Humam Kadara

      • Abstract

      No abstract available for this presentation

  • +

    OA14 - Global Disparities in Lung Cancer Care

    • 18:45 - 19:45
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Global Health
    • +

      OA14.01 - Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

      18:45 - 18:55  |  Presenter: Virginia Calvo

      • Abstract

      Loading...

    • +

      OA14.02 - Social Vulnerability Is an Independent Risk Factor in Patients Undergoing Surgical Treatment of Lung Cancer

      18:55 - 19:05  |  Presenter: Ricardo Mingarini Terra

      • Abstract

      Loading...

    • +

      OA14.03 - Discussant

      19:05 - 19:15  |  Presenter: Nan Wu

      • Abstract

      No abstract available for this presentation

    • +

      OA14.04 - Live Discussion with Speakers

      19:15 - 19:45

      • Abstract

      No abstract available for this presentation

  • +

    OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation

    • 18:45 - 19:45
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      OA15.01 - Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy

      18:45 - 18:55  |  Presenter: Alexander Spira

      • Abstract

      Loading...

    • +

      OA15.02 - Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations

      18:55 - 19:05  |  Presenter: Pasi A. Janne

      • Abstract

      Loading...

    • +

      OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

      19:05 - 19:15  |  Presenter: Alexander Spira

      • Abstract

      Loading...

    • +

      OA15.04 - Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer

      19:15 - 19:25  |  Presenter: D. Ross Camidge

      • Abstract

      Loading...

    • +

      OA15.05 - Discussant

      19:25 - 19:35  |  Presenter: Federico Cappuzzo

      • Abstract

      No abstract available for this presentation

    • +

      OA15.06 - Live Discussion with Speakers

      19:35 - 19:45

      • Abstract

      No abstract available for this presentation